September 03, 2026

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

Symbol: **ORCHPHARMA**

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal
Street, Fort, Mumbai-400001

Scrip Code: **524372**

Subject: <u>Outcome of Board Meeting – Orchid Pharma Limited ("the Company")</u>

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), as amended read with SEBI Master Circular no. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. September 03, 2026 (commenced at 18:00 P.M. (IST) and concluded at 19:45 P.M. (IST) has *inter-alia* considered and approved below mentioned matters:

1. Appointment and recommendation of remuneration of Cost Auditors of the Company for the F.Y. 2026-27. Details as required under Regulation 30 read with SEBI Circular SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026 are enclosed herewith as **Annexure-I**

2. Appointment and remuneration of Mr. Arjun Dhanuka (DIN: 00454689) as Whole-Time Director, who is presently a Non-Executive Non Independent Director of the company. Details as required under Regulation 30 read with SEBI Circular SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026 are enclosed herewith as **Annexure-II**

3. Notice, including explanatory statement therein, for convening 33rd Annual General Meeting of the Company scheduled to be held on September 29, 2026.

4. The cut-off date for determining the shareholders eligible of receiving the notice of ensuing Annual General Meeting scheduled to be held on September 29, 2026, shall be Friday, September 04, 2026 and for e-voting i.e. shareholders eligible to vote on the resolutions in notice of Annual General Meeting, shall be Tuesday, September 22, 2026. The Remote e-voting period will commence on September 26, 2026 (9:00 A.M. 1ST) and ends on September 28, 2026 (5:00 P.M. 1ST).

5. Appointment of e-voting agency for facilitating e-voting including remote e-voting and the appointment of scrutinizer for providing scrutinizer's report thereon.

You are requested to take the above intimations on record.

Thanking You,
For **Orchid Pharma Limited**

KAPIL
DAYYA

Kapil Dayya
Company Secretary & Compliance Officer
Mem. No.- F10698
Encl. as above

Annexure- I

Information as required under Regulation 30 - Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026

(Appointment of Auditor)

Particulars	**Appointment of Cost Auditor for FY 2026-2027**
Name of the Audit Firm/Auditor	M/s. J Karthikeyan & Associates
Reason for change viz. appointment, ~~resignation, removal, death or otherwise.~~	Appointment
Date of appointment & Term of appointment	The Board at their meeting held today i.e. September 03, 2026, 2025, approved the appointment of Cost auditor for the F.Y.2026-27, subject to the ratification of remuneration of the cost auditor by the Members of the Company at the ensuing AGM.
Brief Profile	M/s. J Karthikeyan & Associates, Cost Accountant, Chennai, holding Certificate of Practice issued by the Institute of Cost Accountants of India (Membership No.29934, Firm Registration No.102695) .
Disclosure of relationships between Directors	Nil

OrchidPharma
A Dhanuka Group Company

Annexure- II

Information as required under Regulation 30 - Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026

Sr. No.	Particulars	Information w.r.t Mr. Arjun Dhanuka
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Change in designation
2	Date of appointment/cessation (as applicable) & term of appointment	September 03, 2026 Tenure- September 03, 2026 to September 02, 2031
3	Brief profile (in case of appointment)	Mr. Arjun Dhanuka started his career with Dhanuka Laboratories Limited in September 2010. From 2010-13 his role comprised of managing all the purchase decisions of the Company. He graduated from Delhi University and has served as Whole Time Director of Dhanuka Laboratories Limited. In 2013, he started working with operations team of Synmedic Laboratories. After gaining relevant experience, he supervised majority of operations at Synmedic Laboratories since 2020. He strives in Business Development and strategy building. Mr. Dhanuka is young and dynamic person with an experience of more than a decade in the Pharmaceuticals Sector.
4	Disclosure of relationships between directors (in case of appointment of a director)	As per sec 2 (76) of Companies Act 2013, Mr. Arjun Dhanuka is not related to other Directors and Key Managerial Personnel of the Company

+91-44-2744 4471/72/73 • corporate@orchidpharma.com • orchidpharma.com • CIN: L24222TN1992PLC022994

Registered Office:
Orchid Pharma Limited
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate,
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.

Corporate Office:
15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Gurugram - 122004, Haryana, India